The Scott M. Hammer Annual Update on HIV Management in New York, New York (Offered In-Person and Virtually)

Last Modified: Apr 29, 2026 @ 1:04 PM

Program Description

Join us in New York City for one of the most anticipated IAS–USA annual courses, where science, clinical expertise, and advances in HIV care come together. This dynamic, in-person event at the NYU Skirball Center will convene leading experts and frontline clinicians for an exciting day of learning, discussion, and practical clinical insights. This course is also offered virtually for those unable to attend in person.

Stay on the cutting edge of HIV medicine with timely updates and lively case-based discussions. Highlights include key takeaways from Conference for Retroviruses and Opportunistic Infections (CROI) 2026, an in-depth look at the state of long-acting therapeutics and their use in diverse populations, and a comprehensive session on HIV and pregnancy covering vaccines, treatment and prevention strategies, and breastfeeding guidelines. Engage in interactive antiretroviral therapy case discussions, and explore prevention strategies, vaccine guidelines, management of substance use disorders, and diabetes care in people with and at risk for HIV.

Don’t miss the opportunity to engage with expert faculty and peers and stay at the forefront of HIV management.

IAS–USA Lifetime of Leadership Award

At this course, the IAS–USA is proud to present its Lifetime of Leadership Award—established nearly 15 years ago to honor individuals whose contributions have left a profound and lasting impact on HIV medicine, scientific education, and the mission of the IAS–USA—to Dr Gerald Friedland, longtime cochair of this course and a distinguished leader whose work has shaped the field and inspired generations of clinicians and researchers.

All friends, family, and colleagues of Dr Friedland are welcome to attend the award ceremony virtually at no cost. To do so, select the “Lifetime of Leadership Award Ceremony for Dr Friedland (ONLY)” option when registering.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of clinicians involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and related comorbidities. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
• Review treatment and prevention strategies for HIV and pregnancy, including vaccine and breastfeeding guidance
• Optimize HIV prevention and management in diverse patient populations
• Discuss current vaccine guidelines for people with HIV, including safety, efficacy, and special considerations for children and pregnant women
• Apply evidence-based recommendations for the prevention and management of substance use disorders and comorbidities in people with HIV
• Summarize important considerations for managing persons with HIV and diabetes

Preliminary Topics

• Difficult cases in antiretroviral therapy
• Key updates from CROI 2026
• Long-acting therapeutics: what’s new, who benefits, and how to manage treatment failure
• HIV and pregnancy: vaccines, treatment and prevention strategies, and breastfeeding guidelines
• HIV prevention innovations and implementation strategies
• Vaccine guidelines for people with HIV, including safety and efficacy in special populations
• Substance use disorders: medications for opioid use disorder (MOUD), emerging therapies, and management of comorbidities
• Diagnosis, treatment, and complications of diabetes in people with HIV

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.